Results 21 to 30 of about 206 (110)

Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib [PDF]

Toxins, 2021
Bites from elapid snakes typically result in neurotoxic symptoms in snakebite victims. Neurotoxins are, therefore, often the focus of research relating to understanding the pathogenesis of elapid bites.
Taline D. Kazandjian, Arif Arrahman, Kristina B. M. Still, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Mark C. Wilkinson, Jeroen Kool   +7 more
doaj   +6 more sources

Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920) [PDF]

Scientific Reports, 2019
AbstractThe World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030. In this context, effective adjuvant treatments to complement conventional antivenom therapy based on inhibitory molecules for specific venom toxins ...
Bruno Lomonte, Guilherme H M Salvador, José María Gutiérrez   +2 more
exaly   +7 more sources

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients

Journal of the American College of Cardiology, 2010
The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary syndrome patients.Secretory phospholipase A(2) (sPLA(2)) represents a family of proatherogenic enzymes that hydrolyze lipoprotein phospholipids, increasing their affinity for intimal proteoglycans; contribute to cholesterol loading of ...
Robert S Rosenson
exaly   +6 more sources

Correction: Wang et al. Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules 2018, 23, 391 [PDF]

Molecules, 2022
The authors would like to correct an error in the original publication [...]
Yiding Wang, Jing Zhang, Denghong Zhang, Huixiang Xiao, Shengwei Xiong, Chunhong Huang   +5 more
doaj   +3 more sources

Inhibitory Effects of Varespladib, CP471474, and Their Potential Synergistic Activity on Bothrops asper and Crotalus durissus cumanensis Venoms [PDF]

Molecules, 2022
Snakebite is a neglected tropical disease that causes extensive mortality and morbidity in rural communities. Antivenim sera are the currently approved therapy for snake bites; however, they have some therapeutic limitations that have been extensively ...
Sara Quiroz, Isabel C. Henao Castañeda, Johan Granados, Arley Camilo Patiño, Lina María Preciado, Jaime Andrés Pereañez   +5 more
doaj   +4 more sources

PLA₂ Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera berus nikolskii [PDF]

Toxins, 2020
Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites ...
Oleksandr Zinenko, Igor Tovstukha, Yevgen Korniyenko   +2 more
doaj   +5 more sources

Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation [PDF]

Toxins, 2016
Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a century of calls to improve snakebite prevention and care.
Matthew Lewin, Stephen Samuel, Janie Merkel, Philip Bickler   +3 more
exaly   +4 more sources

Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib) [PDF]

Toxins, 2018
Snakebite is a global tropical disease that has long had huge implications for human health and well-being. Despite its long-standing medical importance, it has been the most neglected of tropical diseases.
Mátyás A. Bittenbinder, Christina N. Zdenek, Bianca op den Brouw, Nicholas J. Youngman, James S. Dobson, Arno Naude, Freek J. Vonk, Bryan G. Fry   +7 more
doaj   +6 more sources

Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial

BMJ Global Health
Introduction Snakebite envenoming (SBE) results in over 500 000 deaths or disabling injuries annually. Varespladib methyl, an oral inhibitor of secretory phospholipase A2, is a nearly ubiquitous component of snake venoms. We conducted a phase II clinical
Chanaveerappa Bammigatti, Timothy F Platts-Mills, Ashish Bhalla, Harish Kumar, Matthew R Lewin, Surendra Kumar, Charles J Gerardo, Rebecca W Carter, Farshad M Shirazi, Suneetha D Kotehal, Peter D Akpunonu, Richard B Schwartz, Neeraj Manikath, Partha P Mukherjee, Thomas C Arnold, Brian J Wolk, Sophia S Sheikh, Dawn R Sollee, David J Vearrier, Samuel J Francis, Adiel Aizenberg, Madhu K Ravikumar, Sujoy Sarkar, Taylor Haston, Andrew Micciche, Suraj C Oomman, Jeffery L Owen, Brandi A Ritter, Stephen P Samuel   +28 more
doaj   +4 more sources

Breaking muscle: neurotoxic and myotoxic effects of Central American snake venoms and the relative efficacies of antivenom and varespladib

BMC Biology
Background The snake genera Atropoides, Cerrophidion, and Metlapilcoatlus form a clade of neotropical pit vipers distributed across Mexico and Central America.
Lee Jones, Mimi Lay, Edgar Neri-Castro, Vanessa Zarzosa, Wayne C. Hodgson, Matthew Lewin, Bryan G. Fry   +6 more
doaj   +4 more sources